Ozempic and Testosterone: Drug Interaction Guide

Ozempic contains semaglutide, a GLP-1 receptor agonist administered via once-weekly subcutaneous injection for type 2 diabetes; the higher-dose formulation Wegovy uses the same active ingredient but is FDA-approved for chronic weight management. In this guide, testosterone refers to prescription testosterone replacement therapy (TRT) administered through FDA-approved routes including intramuscular or subcutaneous injections of cypionate or enanthate, transdermal gels and patches, or oral testosterone undecanoate (Jatenzo). This guide addresses clinician-prescribed testosterone for documented hypogonadism and does not cover compounded formulations or non-prescription testosterone products.

Direct answer: No pharmacokinetic drug interaction has been identified between semaglutide and testosterone. Semaglutide is broken down by proteolytic degradation, not by liver CYP450 enzymes, so testosterone metabolism is not affected and semaglutide's own clearance is not affected by testosterone. The evidence that does matter is pharmacodynamic and physiologic: testosterone's known hematocrit and lipid effects need routine monitoring regardless of concurrent semaglutide, and semaglutide-driven weight loss can raise a man's own testosterone production enough to change how much exogenous testosterone he actually needs. Verification of specific trial figures cited below against the primary publications is recommended before using them in clinical counseling.

Why these two drugs end up prescribed together

Men with obesity, type 2 diabetes, and hypogonadism overlap heavily in clinical practice. Obesity suppresses the hypothalamic-pituitary-gonadal axis, and low testosterone independently worsens insulin resistance and weight gain, so the two conditions can reinforce each other. Endocrine Society guidance on testosterone therapy in men with hypogonadism recommends addressing obesity-associated hypogonadism through weight loss as an initial approach before or alongside testosterone therapy. GLP-1 receptor agonists such as semaglutide have become one of the more effective non-surgical tools for that weight loss, which is why the two drug classes are increasingly co-prescribed rather than seen as one substituting for the other.

A large randomized trial of once-weekly semaglutide 2.4 mg in adults with overweight or obesity (the STEP 1 trial) reported substantially greater mean body weight loss than placebo over about 16 months of treatment. The exact percentage figures commonly cited for that trial should be checked against the original New England Journal of Medicine publication before being used in patient materials, since precise numbers are easy to misquote. Separately, smaller studies and meta-analyses have suggested that meaningful weight loss in obese men can raise total testosterone by tens of ng/dL per 10% of body weight lost, though the exact magnitude varies across studies and should be treated as an approximate, not a guaranteed, effect for any individual patient.

No pharmacokinetic conflict, and why

Semaglutide is a peptide. The FDA-approved prescribing information for Ozempic describes its clearance as proteolytic cleavage of the peptide backbone followed by fatty-acid side chain metabolism, with no meaningful role for CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 (Ozempic label). Testosterone injections and gels, by contrast, are converted to dihydrotestosterone and estradiol through 5-alpha-reductase and aromatase, with only a minor CYP3A4 contribution (per its FDA prescribing information). Because semaglutide does not inhibit or induce CYP3A4, there is no bidirectional metabolic interference between the two drugs at the enzyme level.

Both injectable testosterone and injectable semaglutide also bypass the gut and first-pass hepatic metabolism, so P-glycoprotein transport competition in the intestine is not a relevant pathway for that combination. This is a mechanistic conclusion based on how each drug is absorbed and cleared, not a claim backed by a dedicated interaction trial of the two drugs together, since no such trial appears to have been published.

Where the real overlap is: lipids, hematocrit, and cardiovascular risk

The clinically meaningful overlap between these drugs is pharmacodynamic, not pharmacokinetic, and it runs in two directions.

Lipids. GLP-1 receptor agonist trials, including SUSTAIN-6, have reported modest favorable shifts in LDL cholesterol and triglycerides with semaglutide relative to placebo. Testosterone therapy has a more mixed lipid signal: several studies, including secondary analyses of the Testosterone Trials, have reported a small reduction in HDL cholesterol alongside reductions in triglycerides. The HDL reduction is the detail worth tracking in a patient who already has elevated cardiovascular risk, which describes many men with type 2 diabetes on semaglutide. A fasting lipid panel at baseline and at follow-up is reasonable regardless of which drug started first.

Hematocrit and polycythemia. This is testosterone's most predictable dose-dependent risk, not something semaglutide changes. The FDA label for testosterone cypionate carries a warning for polycythemia, generally described using a hematocrit threshold above 54%. Semaglutide has no established effect on hematocrit or red cell mass, so it does not add to this risk directly, but a patient on both drugs still needs the same hematocrit monitoring a patient on testosterone alone would need.

Cardiovascular outcomes. Testosterone replacement in men with hypogonadism and elevated cardiovascular risk has been evaluated in a large cardiovascular outcomes trial (TRAVERSE), which reported that testosterone was not associated with a higher rate of major adverse cardiovascular events compared with placebo. Semaglutide has separately been evaluated for cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease (SELECT), with a reported reduction in major cardiovascular events versus placebo. These are two separate trials in overlapping but not identical populations, and neither trial tested the two drugs together. It is plausible that the cardiovascular profiles are complementary rather than conflicting, but that is an inference from two separate trials, not a demonstrated finding for combined use. Readers should treat the specific relative-risk figures from these trials as needing verification against the original publications before being repeated as precise numbers.

Evidence-status interaction assessment

Gastric emptying and testosterone formulation

Semaglutide slows gastric emptying, an effect documented in its prescribing information and in postprandial metabolism studies. For intramuscular or subcutaneous testosterone (cypionate, enanthate) and for topical gels or patches, gastric motility is irrelevant because none of those routes depend on stomach emptying for absorption.

Oral testosterone undecanoate (Jatenzo) is the exception. Its FDA label specifies that it must be taken with food because absorption depends on intestinal lymphatic uptake (Jatenzo label). Delayed gastric emptying from semaglutide could in theory shift the timing of that absorption, but no published study has directly tested this combination. A clinician managing a patient on both drugs should treat this as an open question rather than a settled non-issue, and a post-dose testosterone level a few weeks after starting or up-titrating semaglutide is a reasonable, cautious check rather than a guideline requirement.

The weight-loss feedback loop and when to re-evaluate TRT

The most clinically actionable point in this combination is not a drug-drug interaction at all. It is that semaglutide's intended effect, weight loss, can partially reverse the reason a man was started on testosterone in the first place, if his hypogonadism was obesity-related (sometimes called functional or obesity-associated hypogonadism). Several studies report that meaningful weight loss increases endogenous testosterone production in obese men, though the size of the effect differs across studies and cannot be predicted precisely for an individual patient.

Guideline bodies addressing testosterone therapy generally recommend reassessing the ongoing need for TRT after a patient's underlying contributing condition, including obesity, has substantially improved. Practically, this means a man who starts semaglutide while on a stable testosterone dose should have his total and free testosterone rechecked after a significant weight change, rather than assuming the original TRT dose remains correct indefinitely. Some men on TRT plus semaglutide may end up needing a lower testosterone dose, longer injection intervals, or discontinuation altogether once weight loss is substantial; others with a non-obesity cause of hypogonadism will not see this shift at all.

What monitoring looks like in practice

No specialty society has published a monitoring protocol specific to concurrent semaglutide and testosterone use. The following draws on general principles from testosterone prescribing information, diabetes care standards, and standard hypogonadism management, and should be adapted to the individual patient by the prescribing clinician.

Before starting the combination, or at baseline:

• CBC with hematocrit
• Fasting lipid panel
• HbA1c
• Morning total and free testosterone
• PSA, in men over 40, per standard TRT monitoring practice

Around 3 months:

• Hematocrit (testosterone's main safety check)
• HbA1c (to assess glycemic response and guide semaglutide titration)
• Testosterone trough level

At 6 to 12 months, and after any significant weight change:

• Repeat full baseline panel
• Reassess whether the current testosterone dose, or continued TRT at all, is still appropriate

A hematocrit above 54% is the threshold in the FDA testosterone label that generally prompts dose reduction, a longer injection interval, or discontinuation, sometimes with a referral to consider phlebotomy. Rising PSA should be evaluated according to standard urologic practice regardless of semaglutide use.

Patient counseling points

Patients using both medications should keep a few practical points in mind. Semaglutide is injected subcutaneously (abdomen, thigh, or upper arm), while testosterone cypionate or enanthate is typically injected intramuscularly (or subcutaneously for some low-volume protocols). The two should not be mixed in the same syringe or injected at the same site.

Gastrointestinal symptoms such as nausea, vomiting, or diarrhea after starting or increasing a semaglutide dose are common with GLP-1 receptor agonists and are more likely to come from semaglutide than from testosterone. Headache, blurred vision, flushing, or tingling in the extremities can be signs of polycythemia related to testosterone and should be reported promptly, independent of semaglutide use, since testosterone rather than semaglutide is the driver of that risk.

What is established, what is plausible, and what is not established

Established: semaglutide and testosterone do not share a metabolic pathway, and there is no documented pharmacokinetic interaction between them. Testosterone's hematocrit and lipid effects are documented in its own labeling and trial literature and are not altered by semaglutide.

Plausible but not proven as a fixed rule: semaglutide-driven weight loss can raise endogenous testosterone enough to require a lower TRT dose in some men, and delayed gastric emptying could theoretically affect oral testosterone absorption timing.

Not established: any combined cardiovascular effect specific to using both drugs together, since each drug's cardiovascular outcomes data comes from separate trials in overlapping but distinct populations. A dedicated interaction or combination trial does not appear to exist in the published literature reviewed for this guide.

When to seek care sooner

Contact your prescriber promptly, rather than waiting for a scheduled lab draw, for symptoms such as persistent headache, visual changes, chest pain, shortness of breath, calf swelling, or signs of an allergic reaction to either medication. Severe or persistent nausea and vomiting with semaglutide, or symptoms suggesting a very high hematocrit, both warrant timely medical evaluation rather than self-adjustment of either drug's dose.